The biotech industry faces many serious strategic challenges with no obvious solutions. The FDA approved only 22 new drug candidates in 2016—less than half of the prior year, and the lowest level since 2010. Meanwhile, the IPO market collapsed to its lowest level since 2009, and pressure from the government and payers is pushing pricing and value concerns into earlier stages of drug development.

Biopharma companies must increasingly adopt creative dealmaking, new digital technologies and early cost-effectiveness strategies, all while speeding up the R&D process. This requires a novel way of thinking about partnerships and pipeline strategies, from the highest levels of biopharma leadership.

The FierceBiotech 2nd Drug Development Forum draws together the industry's executive decision-makers, to help guide your companies to success throughout the entire lifecycle, both for products and for companies themselves.

WilmerHale Partner Rosemary Reilly will moderate the panel, “Anticipate the Responses and Judgments of Venture Capitalists to a Crowded Market.”